Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center, Leiden, The Netherlands.
Pituitary. 2022 Aug;25(4):587-601. doi: 10.1007/s11102-022-01230-2. Epub 2022 May 26.
To report the first experience of our multidisciplinary team with functional imaging using C-methionine positron emission tomography-computed tomography (C-methionine PET-CT) co-registered with MRI (Met-PET/MRI) in clinical decision making and surgical planning of patients with difficult to treat prolactinoma.
In eighteen patients with prolactinoma, referred to our tertiary referral centre because of intolerance or resistance for dopamine agonists (DA), Met-PET/MRI was used to aid decision-making regarding therapy.
Met-PET/MRI was positive in 94% of the patients. MRI and Met-PET/MRI findings were completely concordant in five patients, partially concordant in nine patients, and non-concordant in four patients. In five patients Met-PET/MRI identified lesion(s) that were retrospectively also visible on MRI. Met-PET/MRI was false negative in one patient, with a cystic adenoma on conventional MRI. Thirteen patients underwent transsphenoidal surgery, with nine achieving full biochemical remission, two clinical improvement and near normalized prolactin levels, and one patient clinical improvement with significant tumour reduction. Hence, nearly all patients (94%) were considered to have a positive outcome. Permanent complication rate was low. Three patients continued DA, two patients have a wait and scan policy.
Met-PET/MRI can provide additional information to guide multidisciplinary preoperative and intraoperative decision making in selected cases of prolactinoma. This approach resulted in a high remission rate with a low rate of complications in our expert centre.
报告我们的多学科团队在使用 C-蛋氨酸正电子发射断层扫描-计算机断层扫描(C-蛋氨酸 PET-CT)与磁共振成像(Met-PET/MRI)融合的功能成像在治疗困难性泌乳素瘤患者的临床决策和手术计划中的首次经验。
在 18 例因多巴胺激动剂(DA)不耐受或耐药而转诊至我们的三级转诊中心的泌乳素瘤患者中,使用 Met-PET/MRI 来辅助治疗决策。
Met-PET/MRI 在 94%的患者中呈阳性。MRI 和 Met-PET/MRI 检查结果在 5 例患者中完全一致,在 9 例患者中部分一致,在 4 例患者中不一致。在 5 例患者中,Met-PET/MRI 识别出了回顾性可见的 MRI 病变。在 1 例患者中,Met-PET/MRI 为假阴性,MRI 显示为囊性腺瘤。13 例患者接受了经蝶窦手术,其中 9 例达到了完全生化缓解,2 例临床改善且泌乳素水平接近正常,1 例患者临床改善且肿瘤显著缩小。因此,几乎所有患者(94%)都被认为有积极的结果。永久性并发症发生率较低。3 例患者继续使用 DA,2 例患者采用等待和扫描策略。
Met-PET/MRI 可以提供额外的信息,以指导选择病例的泌乳素瘤的多学科术前和术中决策。在我们的专家中心,这种方法导致了高缓解率和低并发症率。